- Home
- JGH vs MGTX Comparison
JGH vs MGTX Comparison
Compare JGH & MGTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | JGH | MGTX |
|---|---|---|
| Founded | 2014 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Investment Managers | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 285.5M | 610.1M |
| IPO Year | N/A | 2018 |
Fundamental Metrics
Financial Performance| Metric | JGH | MGTX |
|---|---|---|
| Price | $12.37 | $9.06 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 7 |
| Target Price | N/A | ★ $22.86 |
| AVG Volume (30 Days) | 83.3K | ★ 528.2K |
| Earning Date | 01-01-0001 | 05-12-2026 |
| Dividend Yield | ★ 9.85% | N/A |
| EPS Growth | N/A | ★ 33.02 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $81,391,000.00 |
| Revenue This Year | N/A | $118.35 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 144.57 |
| 52 Week Low | $10.51 | $4.73 |
| 52 Week High | $13.70 | $9.73 |
Technical Indicators
Market Signals| Indicator | JGH | MGTX |
|---|---|---|
| Relative Strength Index (RSI) | 49.29 | 71.21 |
| Support Level | N/A | $7.21 |
| Resistance Level | $12.94 | $9.33 |
| Average True Range (ATR) | 0.19 | 0.49 |
| MACD | -0.00 | 0.16 |
| Stochastic Oscillator | 74.36 | 91.18 |
Price Performance
Historical ComparisonAbout JGH Nuveen Global High Income Fund of Beneficial Interest
Nuveen Global High Income Fund operates as a diversified closed-end management investment company. Its investment objective is to provide a high level of current income. The Fund's securities include U.S. high-yield bonds; non-U.S. high-yield bonds from developed and emerging markets; and other income-producing investments such as preferred and convertible securities.
About MGTX MeiraGTx Holdings plc
MeiraGTx Holdings PLC is a clinical-stage gene therapy company. It focuses on the eye, salivary gland, and central nervous system disorders. The company's pipeline products include AAV-CNGB3, AAV-CNGA3 and AAV-RPGR, and others. Geographically, it operates in the United States, the United Kingdom, and European Union.